NCT07677059RecruitingPhase 2
A Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma Study
A Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Safety and Tolerability of KT-621 in Participants With Asthma Previously Enrolled in a KT-621 Asthma Study
Source: ClinicalTrials.gov · Last updated 7 Oct 2026
Brief summary (registry, in English)
This Phase 2b open-label, long-term extension study is designed to evaluate the long-term safety and efficacy of KT-621 in participants with asthma who were previously enrolled in the parent study (KT621-AS-202) of KT-621 for asthma. The main goals of this study are to investigate the long-term safety and tolerability of KT-621, the long-term efficacy of KT-621 at treating asthma, and how KT-621 behaves in the body long-term.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 264 (estimated)
- First submitted
- 24 Jun 2026
- Start date
- 25 Jun 2026
- Primary completion date
- Dec 2028
- Lead sponsor
- Kymera Therapeutics, Inc.
- Diseases
- Asthma
- NCT number
- NCT07677059
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 264
- From 25 Jun 2026 to the primary completion date, Dec 2028
- 7 sites in 4 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Must not have experienced any clinically significant change in health status during the parent study, which, in the opinion of the Investigator, would interfere with participant safety, study evaluations, or compliance with study procedures; or otherwise make the participant unsuitable for participation in this study.
- Must not have developed an AE during the parent study, that in the opinion of the Investigator or of the Sponsor's Medical Monitor, could indicate that continued treatment may present an unreasonable risk for the participant.
- Must not have met permanent discontinuation criteria and/or permanently discontinued study treatment for any reason during the parent study.
- Must not be a member of the Sponsor or site's investigational team or their immediate family.
- Must not be unsuitable to enter the study for any other reason, as judged by the Investigator, including potential risk of noncompliance to study procedures.
Who the study is looking for
- Must have completed all visits of the parent study, per its protocol, up to the end of treatment (EoT) visit.
- Must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, other study-related procedures, and questionnaires, including completing the electronic diary (e-diary), for the duration of the study as required by the study protocol.
- Must agree to contraceptive requirements in compliance with the clinical study and local requirements.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (7)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Berlin | Germany | Recruiting |
| - Coordinator of this site? Confirm its status | Poznan | Poland | Recruiting |
| - Coordinator of this site? Confirm its status | Kamenitz | Serbia | Recruiting |
| - Coordinator of this site? Confirm its status | Užice | Serbia | Recruiting |
| - Coordinator of this site? Confirm its status | Dallas | United States | Recruiting |
| - Coordinator of this site? Confirm its status | Miami | United States | Recruiting |
| - Coordinator of this site? Confirm its status | Tampa | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.